Summary of study ST000276

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000154. The data can be accessed directly via it's Project DOI: 10.21228/M8688J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data
Study IDST000276
Study TitleIDH1 and Glioma knockdown idh1
Study SummaryThis study is a part of series performed for the same researcher through pilot/feasibility grant program, so the publication is relevant reference for other studies (ST000199) This specific experiment is a pilot study to compare the metabolism of cells transformed using empty vector against cells transformed with vector carrying short hairpin RNA (shRNA) targeted to silence isocitrate dehydrogenase-1 (IDH1) gene.
Institute
University of Michigan
DepartmentNeurology
LaboratoryStegh Lab (Northwestern University)
Last NameCalvert
First NameAndrea
AddressEvanston, IL
Emaila-calvert@u.northwestern.edu
Phone312-503-3134
Submit Date2014-06-11
Num Groups2
Total Subjects10
Study CommentsSubject IDs are updated to correcly show before/after exercise samples taken from the same person
Analysis Type DetailGC/LC-MS
Release Date2016-01-13
Release Version1
Andrea Calvert Andrea Calvert
https://dx.doi.org/10.21228/M8688J
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000154
Project DOI:doi: 10.21228/M8688J
Project Title:Isocitrate dehydrogenase-1 and Glioma Studies
Project Summary:Dr. Stegh will define the role of a novel glioma oncoprotein, termed isocitrate dehydrogenase-1 (IDH1), in driving progression and therapy resistance of glioblastoma (GBM). Understanding the molecular basis of the therapy refractoriness of GBM is one of the most important areas of glioma research.IDH1 is a critical enzyme of the citric acid cycle (CAC) and is a master regulator of metabolism. Building on his preliminary studies, Dr. Stegh will molecularly characterize the precise mechanism, by which IDH1 protects glioma cells from therapy-induced cell death using glioma cell and mouse models. To target IDH1 signaling in GBM, he will leverage these model systems and mechanistical knowledge to develop and preclinically characterize RNA interference RNAi-based nanomaterials. He will generate RNAi-functionalized spherical nucleic acids (SNAs) that neutralize IDH1 expression in established gliomas. Due to the negative charge of the RNA backbone, however, siRNA oligonucleotides have many downsides, such as they trigger auto-immune responses, and cannot cross the blood-brain-barrier (BBB). In contrast, SNAs are able to transverse cellular membranes, do not require the use of toxic auxiliary reagents, and accumulate in cells and intracranial tumors very effectively. They also exhibit extraordinary stability in physiological environments, cross the BBB, are highly resistant to nuclease degradation, and thus, can move through biological fluids and avoid being destroyed as “foreign materials.” Dr. Stegh proposes to preclinically evaluate these IDH1-targeting nanoconjugates to provide a fundamentally novel treatment option of patients diagnosed with GBM, and will aid in successfully implementing RNAi-based therapies into neuro-oncological practice.
Institute:Northwestern University
Department:Neurology
Laboratory:Stegh Lab
Last Name:Stegh
First Name:Alexander
Address:Evanston, IL
Email:a-stegh@northwestern.edu
Phone:312-503-2879

Subject:

Subject ID:SU000296
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id IDH1 Knockdown
SA012219S00014999No
SA012220S00015002No
SA012221S00015003No
SA012222S00015001No
SA012223S00015000No
SA012224S00015007yes
SA012225S00015008yes
SA012226S00015005yes
SA012227S00015004yes
SA012228S00015006yes
Showing results 1 to 10 of 10

Collection:

Collection ID:CO000290
Sample Type:Cells, Cultured

Treatment:

Treatment ID:TR000310

Sample Preparation:

Sampleprep ID:SP000304
Sampleprep Protocol Filename:Gly-TCA-nucleotides_analysis_protocol-2015-03-09.docx

Combined analysis:

Analysis ID AN000440 AN000441
Analysis type MS MS
Chromatography type HILIC GC
Chromatography system Agilent 1260 Agilent 7890A
Column Phenomenex Luna NH2 (150 x 1mm, 3um) Agilent DB5-MS (30m × 0.25mm, 0.25um)
MS Type ESI EI
MS instrument type QTOF Single quadrupole
MS instrument name Agilent 6530 QTOF Agilent 5975C
Ion Mode POSITIVE POSITIVE
Units pmol/µg protein pmol/µg protein

Chromatography:

Chromatography ID:CH000311
Methods ID:AQM020
Methods Filename:QTOF-002-HILIC-35min-1mm.m
Instrument Name:Agilent 1260
Column Name:Phenomenex Luna NH2 (150 x 1mm, 3um)
Chromatography Type:HILIC
  
Chromatography ID:CH001307
Methods ID:AQM011
Methods Filename:ALPHA_KETO_ACIDS-FULL.M.zip
Instrument Name:Agilent 7890A
Column Name:Agilent DB5-MS (30m × 0.25mm, 0.25um)
Chromatography Type:GC

MS:

MS ID:MS000381
Analysis ID:AN000440
Instrument Name:Agilent 6530 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:POSITIVE
  
MS ID:MS000382
Analysis ID:AN000441
Instrument Name:Agilent 5975C
Instrument Type:Single quadrupole
MS Type:EI
Ion Mode:POSITIVE
  logo